Concepedia

Publication | Closed Access

Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study.

69

Citations

31

References

2013

Year

Fable Zustovich, Lorenza Landi, Giuseppe Lombardi, Camillo Porta, Luca Galli, Andrea Fontana, D. Amoroso, C. Galli, M. Andreuccetti, Alfredo Falcone,
PubMed

Abstract

This combination of sorafenib and temozolomide was feasible and safe, showing some activity in patients with relapsed GBM.

References

YearCitations

Page 1